The exclusive company in the field of regenerative medicine, the CGBIO (President Yu Hyun-seung), announced on January 24, 2022 that its renewal version of CURAVAC, the wound therapeutic instrument exploiting negative vacuum pressure, acquired an approval of product change from the National Medical Products Administration (NMPA) in China
Previous model of CURAVAC acquired an approval of product from the NMPA in 2012.
CURAVAC applies negative pressure to wounds, relieves swelling through continuous suction of exudation from wounds, protects wounds by preventing contamination. It also increases blood flow, thereby promoting the creation capillary vessels and granulation tissue.
The product is generally applicable to chronic wounds such as bedsores and venous ulcer and acute wounds such as external wounds and burns.
Renewal version of CURAVAC accomplished the improved convenience and reduced time for application of the product compared to its previous model by ameliorating five parts: the Drape, Suction Head, Process and Specification of Packaging, Dressing Method, and Suction Tube.
The ‘Drape’ of existing model employs a release paper which is susceptible to breaking, whereas that of the renewed product exploits the invulnerable film material. Further, the two sheets of ‘Drape’ were used for the composition of the bigger and ample size of (26×15) of the form.
The part of ‘Suction Head’ of the product was modified into an integral type from the previous type of assembly to minimize the leakage of negative pressure, which is free from the process of tube assembly, resulting in simplification of dressing procedure via reduction in time of application of the product.
Besides, contrary to the type of previous model of product which is held in a pouch, the type of renewed product employs a process of fully automated vacuum pressure packaging process by which the size of package and risk of contamination were diminished greatly, thereby providing users with the benefit of less occupancy in space.
President Yu Hyun-seung stated, “… the previous model of CURAVAC has been ranked the second in Chinese market share among imported negative vacuum pressure wound therapeutic instruments. Convenience in application of the product by medical staffs in China is anticipated through the release of a more upgraded product. It could also promote the increase in market share greatly…”. “… CGBIO will make efforts continuously to provide medical staffs and patients in the world including China with more excellent and advanced products…”.
